2024-03-28T09:18:19Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00023717
2022-12-15T03:53:54Z
453:456
471:537:538:1228
1) プロラクチン産生腺腫(シンポジウム ホルモン産生下垂体腺腫の臨床, 第427回新潟医学会)
1) プロラクチン産生腺腫(シンポジウム ホルモン産生下垂体腺腫の臨床, 第427回新潟医学会)
Prolactinoma(Clinical Aspects of Hormone-secreting Pituitary Adenomas)
三宅, 崇雄
荒川, 修
丸山, 晋司
西村, 満
阿久津, 正
三沢, 芳夫
佐藤, 芳昭
prolactinoma
bromocriptine
プロラクチン産生腺腫
ブロモクリプチン
Computerized, tomography (CT scan) has now become a most useful method to determine the presence or absence, and extension of pituitary adenoma, Endocrinologically, 75 percent of patients with prolactinoma show abnormally high PRL levels over 200 ng/ml, but most patients with functional GAS show the levels under 200 ng/ml. Hardy's operation has been employed for the selective removal of macroadenoma (> 1cm in diameter) and microadenoma, and that is effective in restoring menstrual function and eliminating lactation in most women. In case of microadenoma, however, conservative therapy with bromocriptine which is highly successful in inducing ovulation and in tumor regression can be indicated. No significant increases in the rate of spontaneous abortion, multiple pregnancy, and newborn anomaly were recognized in pregnancies treated with bromocriptine therapy.
新潟医学会
1987-11
jpn
departmental bulletin paper
http://hdl.handle.net/10191/36934
https://niigata-u.repo.nii.ac.jp/records/23717
AN00182415
00290440
新潟医学会雑誌
新潟医学会雑誌
101
11
697
702
https://niigata-u.repo.nii.ac.jp/record/23717/files/101(11)_697-702.pdf
application/pdf
445.9 kB
2019-08-19